Gillian Ellsbury, United Kingdom
Pfizer UK Ltd Vaccines, Medical AffairsPoster Author Of 1 e-Poster
THE PROPORTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMOCOCCAL PNEUMONIA IN UK ADULTS POTENTIALLY COVERED BY THE 13-VALENT AND NEXT-GENERATION HIGHER-VALENCY PNEUMOCOCCAL CONJUGATE VACCINES UNDER DEVELOPMENT
Author Of 1 Presentation
THE PROPORTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMOCOCCAL PNEUMONIA IN UK ADULTS POTENTIALLY COVERED BY THE 13-VALENT AND NEXT-GENERATION HIGHER-VALENCY PNEUMOCOCCAL CONJUGATE VACCINES UNDER DEVELOPMENT (ID 787)
Abstract
Background
In the UK adults aged 65+ years and those at increased risk of pneumococcal infection are offered a single dose of the 23-valent pneumococcal polysaccharide vaccine (PPV23). PCV-13 is currently used for routine infant immunisation and severely immunocompromised individuals but has an adult indication, and next generation higher valency PCVs (PCV-15 and PCV-20) are anticipated to shortly become available for use in adults.
Methods
Recent peer reviewed publications describing the contemporary pneumococcal disease burden in UK adults were identified. The serotype distribution reflected by PCV-13, PCV-15 and PCV-20 was determined.
Results
The burden of adult pneumococcal disease in the UK remains substantial with no discernible impact of PPV23 at the population level. In 2016/17 the proportion of PCV-13, PCV-15 and PCV-20 IPD in adults aged 65+ years was 21%, 32% and 63% respectively. Between 2013/14 and 2017/18 the average proportion of PCV-13, PCV-15 and PCV-20 pneumococcal pneumonia in adults aged 16+ years was 35%, 40% and 66% respectively (36%, 39% and 64% in 2017/18).
Conclusions
Vaccinating UK adults with PCV-13 could address a significant proportion of the contemporary adult pneumococcal disease burden. Higher valency PCVs provide increased coverage of serotypes currently causing adult disease, with PCV-20 potentially addressing ~65% of the burden.